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The chromosome-encoded class C -lactamase CHE-1 produced by Enterobacter cloacae exhibits a lower sensitivity to avibac-
tam than the P99 enzyme fromwhich it is derived by a 6-residue deletion in the H-10 helix. In the present study, we investigated
the sensitivity of CHE-1 to two other -lactamase inhibitors: LK-157 (or Lek 157), a tricyclic -lactam, and BAL29880, a bridged
monobactam.With both compounds, the second-order rate constants for inactivation were significantly lower for CHE-1, which
can thus be considered an inactivator-resistant mutant of P99. However, the second-order rate constant for the inactivation by
BAL29880 probably remains adequate for a rather rapid reaction with CHE-1 in the absence of protection by the substrate.
Among Gram-negative bacteria, the production of -lactama-ses represents the major mechanism of resistance toward
-lactam antibiotics. Based on their amino acid sequences, -lac-
tamases have been divided into molecular classes A, C, and D,
which contain active serine enzymes and molecular class B met-
alloenzymes that require zinc ions for their activity (1, 2, 3). The
genes coding for class C -lactamases (1, 4) are located on trans-
ferable plasmids, transposons, or the bacterial chromosome.
In this paper, we report the characterization of the interaction
between the chromosome-encoded Enterobacter cloacae CHE-1
enzyme and two very different inactivators. The strain producing
this class C -lactamase was first isolated in 1998, from a child,
previously treated with cefepime, at the Robert Debre Hospital in
Paris, France. The enzyme was purified and was shown to have an
increased catalytic efficiency with cefpirome and cefepime, 10
times higher than that of the E. cloacae P99 enzyme. Sequencing of
the AmpC CHE-1 gene showed that it corresponded to the P99
gene from which 18 nucleotides, encoding residues 289 to 294,
had been deleted. According to the crystal structure of P99, this
deletion is located in the H-10 helix. The authors suggested that
this deletion could be involved in the increased activity against
cefepime and cefpirome and that, consequently, the CHE-1-lac-
tamase could be the first variant conferring resistance to cefepime
and cefpirome (5, 6). Four additional substitutions, situated far
away from the active site, were not expected to significantly influ-
ence the activity.
In addition to its modified substrate profile, compared to the
P99 -lactamase, the CHE-1 enzyme was recently shown to ex-
hibit a 10- to 30-fold-decreased sensitivity to avibactam, a novel
non--lactam -lactamase inactivator (7, 8, 9). In the present
study, we explored the sensitivity of the CHE-1 -lactamase to
more-classical -lactam inactivators: LK157, a tricyclic -lactam
(10–12), and BAL29880, a bridged monobactam (13–15).
MATERIALS AND METHODS
Antibiotics and other chemicals. Nitrocefin (ε482  17,500 M
1
cm1) was purchased from Unipath Oxoid (Basingstoke, United King-
dom), and BAL29880 (Basilea Pharmaceutica International Ltd., Basel,
Switzerland) and LK157 (LEK Pharmaceuticals, Ljubljana, Slovenia) were
provided by the respective companies. Isopropyl--D-thiogalactopyrano-
side (IPTG) and kanamycin were purchased, respectively, from Eurogen-
tech (Liège, Belgium) and Merck (Darmstadt, Germany).
Bacterial strains and vectors. The pBK-CMV phagemid vector was a
gift from Trenon Hospital (Paris, France). pGEM-T Easy vector (Nova-
gen, Inc., Madison, WI) was used to clone the PCR products. The expres-
sion plasmid pET26b() (Novagen, Inc.) was used for the construction of
the T7-based expression vector and for recombinant experiments. Esche-
richia coli BL21(DE3)(pLysS) was used as the host strain in cloning exper-
iments.
Constructionof the cloning vector.To allow the removal of the signal
peptide, the NdeI and HindIII restriction sites were introduced into
blaCHE-1 after the signal peptide nucleotide sequence. These sites were
generated by PCR. The primers were 5=-CCCATATGATGAAAAAATC
CCTTTGC-3= (NdeI) and 5=-CCAAGCTTTTACTGTAGCGCCTC-3=
(HindIII) (the newly introduced restriction sites are underlined).
PCR conditions were as follows: incubation at 95°C for 1 min, fol-
lowed by 40 cycles of amplification (denaturation at 95°C for 1 min, an-
nealing at 55°C for 1 min, and extension at 68°C for 2 min), using Pfu
polymerase (Promega). The PCR product (1,200 bp) was purified using a
miniprep kit and amplified using Taq polymerase for 30min at 72°C. The
PCR product was cloned into the pGEM-T Easy vector to obtain the
recombinant plasmid CHE-1_C1, which was used to transform E. coli
DH5 competent cells. The nucleotide sequences of the PCR-generated
fragments were verified in order to rule out the presence of unwanted
mutations. The CHE-1_C1 plasmid was digested with the NdeI and Hin-
dIII restriction enzymes, and pET26b() (Novagen, Inc.) was digested
with the same restriction enzymes in order to subclone into the
pET26b() vector. The new plasmid, CHE-1_P1, was introduced into E.
coli BL21(DE3) (pLysS) competent cells for production.
-Lactamaseproduction andpurification.CHE-1 expressionwas in-
duced in 1.5 liters of brain heart infusion (BHI) medium at 37°C using 1
mM IPTG. After 4 h, the culture was centrifuged and the bacterial pellet
was resuspended in 40 ml of 15 mM cacodylate, pH 6, containing 1 M
NaCl (buffer A). After two freeze-thaw cycles, bacteria were disrupted by
three sonication cycles for 35 s each at 10W. Cell debris were removed by
centrifugation at 20,000 g and 4°C for 1 h. The supernatant was dialyzed
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overnight at 4°C against 10 liters of buffer A. After filtration through a
0.22-	mmembrane (Millipore), the crude extract (conductivity of 1,700
	S/cm) was loaded onto an SP-FF column (1.6 by 20 cm; Pharmacia,
Sweden) previously equilibrated with buffer A. The column was washed
with buffer A until the A280 of the effluent was
0.1, and the enzyme was
eluted using a linear salt gradient from 0 to 0.5MNaCl in buffer A over 15
column volumes, at a flow rate of 2 ml/min. The active fractions were
pooled and dialyzed overnight at 4°C against 10mMNaphosphate buffer,
pH 6.8 (buffer B). The protein solution (conductivity of 1.25 	S/cm) was
loaded onto a hydroxyapatite Econo-Pac CHT II column (1 by 5 ml;
Bio-Rad) previously equilibrated with buffer B, at 1 ml/min. The elution
was performed with a linear gradient by using 400 mM Na phosphate
buffer, pH 6.5. The fractions that exhibited -lactamase activity were
pooled (30 ml), and the final concentration was 0.65 mg/ml. The enzyme
preparation was stored at20°C in buffer B.
N-terminal sequencing. The N-terminal amino acid sequence of
CHE-1 was determined with the help of an automated Procise protein
sequencing system connected to a Macintosh 650 computer (Perkin-El-
mer Corp., Wellesley, MA).
Mass spectrometry. The molecular mass of the CHE-1 enzyme was
determined by electrospray ionization-quadrupole time of flight mass
spectrometry (ESI–Q-TOF MS). Sodium ions were largely removed by
three cycles of concentration/dilution in 25 mM ammonium acetate buf-
fer by filtration and centrifugation, using an Amicon system (Amicon
Ultra-15; Millipore) with a molecular mass cutoff of 30,000 Da. The anal-
ysis was performedunder acidic conditions in the presence of 0.5% formic
acid, final concentration (pH 3.0).
Kinetic parameters.The steady-state kinetic parameters of CHE-1 for
nitrocefinwere determined as follows. The hydrolysis of the antibiotic was
monitored by recording the absorbance variation at 482 nm in 50 mM
sodium phosphate buffer (pH 7.0) in a total volume of 500 	l at 37°C.
Measurements weremadewith anUvikonXL spectrophotometer. Bovine
serum albumin was added at a final concentration of 10	g/ml in order to
prevent the denaturation of the enzyme. The kinetic parameters (Km and
kcat) were determined by analysis of the complete hydrolysis time courses,
as described by De Meester et al. (16), or by measuring initial rates and
using the Hanes linearization of the Henri-Michaelis equation.
The interactions of LK157 andBAL29880with theCHE-1-lactamase
were studied at 30°C in 50 mM sodium phosphate, pH 7.0, containing 50
mMNaCl and 0.1mg/ml of bovine serum albumin. The enzyme (12 to 24
ng) was incubated for about 5 min at 30°C with 100 	M nitrocefin as the
reporter substrate and inactivator concentrations varying from 0 to 125
	Mfor LK157 or 0 to 30	Mfor BAL29880. The absorbancewas recorded
at 482 nm for a period of 5 min. The values of the pseudo-first-order rate
constants (ki) were determined according to the reporter substrate
method (16) and were plotted as a function of the inactivator concentra-
tions.
The interactions of BAL29880 and LK157 with the P99 -lactamase
were monitored at 30°C in 100mMHEPES buffer, pH 7.5, containing 0.2
MNaCl and 0.1 mg/ml of bovine serum albumin. The enzyme (20 to 100
ng) was added to a 250 	M solution (BAL29880) or a 234 	M solution
(LK157) of the reporter substrate (cephalosporin C), containing 0 to 0.5
	M BAL29880 or 0 to 1.2 	M LK157. The absorbance at 260 nm was
recorded for a period of 80 to 120 s. The ki values were calculated and
plotted as described above.







E P, whereX is the inactivator, E the enzyme,
EX a noncovalent complex, and EX* the acylenzyme. K is the dissociation
constant of EX, and k2 and k3 are first-order rate constants.
Note that, as far as class C-lactamases are concerned, the reactivation
(k3) step has been described for the interaction between LK157 and the
Enterobacter cloacae 908R enzyme (10) but not for the interaction between
BAL29880 and the FOX-4, CMY-2, or CMY-32 enzyme (14, 15). In the
case of LK157 and 908R, this reactivation is very slow (k3 4 10
5 s1,
half-life [t1/2] 290 min) and does not significantly influence the prop-
erties of the inactivator. Nevertheless, we preferred to analyze the results
on the basis of the complete model.
Thepseudo-first-order rate constant for the inactivation is determinedby
ki k3  k2X ⁄ K X, where K= K(Km [R])/Km. Km and [R]
are, respectively, the Km and concentration of the reporter substrate.
The ratio (Km  [R])/Km is referred to as the correction factor in
the calculation of k2/K. When [X] is much smaller than K=,
ki k3  k2X ⁄ K  X simplifies to ki k3  k2X⁄K, and if
k3 is small, the line ki versus [X] extrapolates at or near the origin.
RESULTS
Purification and characterization of the enzyme. The purifica-
tion yield was estimated at 65%. SDS-gel electrophoresis andmass
spectrometry indicated a degree of purity higher than 95%. The
N-terminal sequencing of the mature form of the CHE-1 -lacta-
mase was H2N-TPVSE, identical to those of the P99 and 908R
enzymes (12).
The molecular mass of the CHE-1 enzyme as determined by
ESI–Q-TOF MS was 38,708 4 Da (expected, 38,705 Da) under
denaturing conditions.
Kinetic results. The Km and kcat values of the CHE-1 enzyme
for nitrocefin were, respectively, 9.4 1 	M and 17 1 s1.
Figures 1 to 3 show the influence of the inactivator concentra-
tions on the ki values for the CHE-1–BAL29880 (Fig. 1), P99-
BAL29880 (Fig. 2), and CHE-1–LK157 (Fig. 3) interactions. In all
cases, the ki values vary with the concentration of the inactivators
in a linear way and extrapolate very close to the origin for zero
concentration. These results show that, in all cases, [X] is much
smaller than K= and ki  k3  k2X ⁄ K applies. Similarly, k3 is
much smaller than k2 [X]/K=, so that ki k2X ⁄ K.
The slopes of the lines give the values of k2/K=, i.e., 253 2M1
s1 for CHE-1–BAL29880, 41,000  2,000 M1 s1 for P99-
BAL29880, and 23  0.4 M1 s1 for CHE-1–LK157. Similarly,
for the P99-LK157 interaction, the slope of the line was 20,600
1,000 M1 s1 (not shown).
In the case of P99, the Km value for the reporter substrate
(cephalosporin C) is 400 	M (17), so that the correction factors
are 1.62 (BAL29880) and 1.58 (LK157) and the k2/K values are
66,000 3,000 M1 s1 for BAL29880 and 32,500 0.1600 M1
s1 for LK157.
With the CHE-1 enzyme, the nitrocefin concentration (100
	M) is much larger than the Km value so that a large correction
factor (11.6 1.2) must be introduced and the second-order rate
constant (k2/K) values are 2,900 300M
1 s1 and 270 30M1
s1 for BAL29880 and LK157, respectively.
As mentioned above, the lines extrapolate very close to the
FIG 1 Variation of ki versus [BAL29880] for CHE-1.
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origin so that it can be concluded that k3 is smaller than 10
4 s1.
Note that for the E. cloacae 908R -lactamase the reactivation rate
constant with LK-157 was 0.4 104 s1 and the k2/K value was
36,000 M1 s1 (10). Since the kinetic properties of the 908R and
P99 enzymes are consistently very similar (18), the fact that the
k2/K values for the interactions between each of the enzymes and
LK157 (32,500 M1 s1for P99 versus 36,000 M1 s1 for 908R)
were similar was not surprising.
DISCUSSION
The purifiedCHE-1 enzyme exhibits the expectedmolecularmass
and is significantly more resistant to both inactivators than both
the P99 and 908R -lactamases. The latter enzymes can be con-
sidered equivalent; they differ by only four mutations that do not
significantly affect the enzyme activity (18, 19). Interestingly, two
of themutations present in 908R (I16V andA88P) are also present
in CHE-1, a result which confirms that these mutations have little
influence on the properties of the enzyme. Table 1 highlights the
differences among the three sequences. The mutations at posi-
tions 16, 88, 242, 299, and 342 are situated far away from the active
site, and it is very unlikely that they would modify the kinetic
properties of the enzymes. The substitution of Lwith V at position
132 of 908R is very conservative and also unlikely to result in
significant influence on the enzymatic properties.
In contrast, the deletion at residues 289 to 294, which is close to
the active site, is specific to CHE-1 and is very probably responsi-
ble for the decreased sensitivity to inactivators. It is very interest-
ing to note that avibactam (8), LK157, and BAL29880 exhibit very
different structures and that the CHE-1 inactivation rates by these
compounds decrease in all cases compared to rates of inactivation
of the “parent” enzymes P99 and 908R (10- to 30-fold for avibac-
tam, 14-fold for BAL29880, and more then 100-fold for LK157).
Among the three inactivators discussed above, BAL29880 ex-
hibits the highest k2/K value with the CHE-1 -lactamase (2,900
M1 s1). This value is only about 4-fold lower than the equiva-
lent acylation rate constants of the CMY-2, CMY-32, and FOX-4
class C -lactamases (15, 16), so BAL29880 can still be considered
a fair inactivator of CHE-1. Indeed, if one assumes a 5 	M (2
	g/ml) concentration of BAL29880 in the periplasm, the inacti-
vation half time of CHE-1 would still be about 46 s, which should
be adequate for a rather rapid inactivation. However, it should be
kept in mind that a substrate with a very low Km value affords
some degree of protection, as reported above for nitrocefin.
In conclusion, the class C -lactamase CHE-1 can be consid-
ered an “inactivator-resistant” mutant of P99, and this resistance
is very probably due to the deletion of the hexapeptide at positions
289 to 294. If one considers the homogeneity of class C enzymes
fromboth structural and functional points of view, the probability
that the same deletion in other class C enzymes will result in sim-
ilarly increased resistance to inactivators is rather high. This is not
a very encouraging perspective, and one can only hope that the
CHE-1 mutant remains exceptional. However, the positive result
of the present study is the fact that BAL29880 retains a fair activity
against CHE-1. Although the k2/K value is decreased 20-fold com-
pared to that with P99, it is only 3- to 4-fold lower than those with
FOX-4, CMY-2, and CMY-32. With strains producing these en-
zymes, the addition of BAL29880 at 4 	g/ml (about 10 	M) re-
stores the activity of -lactamase-sensitive compounds (14, 15).
The situation might not be very different with strains producing
modified enzymes similar to CHE-1.
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